A Signature of Immune-related Gene Pairs (IRGPs) for Risk Stratification and Prognosis of Oral Cancer Patients

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2022 Jul 8

PMID 35804390

Authors

Yanling Yu

Jing Tian

Yanni Hou

Xinxin Zhang

Linhua Li

Peifu Cong

Lei Ji

Xuri Wang

Affiliations

Soon will be listed here.

Abstract

Background: With low response to present immunotherapy, it is imperative to identify new immune-related biomarkers for more effective immunotherapies for oral cancer.

Methods: RNA profiles for 390 oral cancer patients and 32 normal samples were downloaded from The Cancer Genome Atlas (TCGA) database and differentially expressed genes (DEGs) were analyzed. Immune genesets from ImmPort repository were overlapped with DEGs. After implementing univariate Cox analysis and the least absolute shrinkage and selection operator (LASSO) Cox regression analysis, key immune-related gene pairs (IRGPs) among the overlapped DEGs for predicting the survival risk were obtained. Then, the cutoff of risk score was calculated by the receiver operating characteristic (ROC) curve to stratify oral cancer patients into high and low-risk groups. Multivariate Cox analysis was used to analyze independent prognostic indicators for oral cancer. Besides, infiltration of immune cells, functional annotation, and mutation analysis of IRGPs were conducted. Biological functions correlated with IRGPs were enriched by Gene Set Enrichment Analysis (GSEA) method.

Results: We identified 698 differentially expressed genes (DEGs) in response to oral cancer. 17 IRGPs among the DEGs were identified and integrated into a risk score model. Patients in the high-risk group have a significantly worse prognosis than those in the low-risk group in both training (P<0.001) and test (P=0.019) cohorts. Meanwhile, the IRGP model was identified as an independent prognostic factor for oral cancer. Different infiltration patterns of immune cells were found between the high- and low-risk groups that more types of T and B cells were enriched in the low-risk group. More immune-related signaling pathways were highly enriched in the low-risk group and Tenascin C (TNC) was the most frequently mutated gene. We have developed a novel 17-IRGPs signature for risk stratification and prognostic prediction of oral cancer.

Conclusion: Our study provides a foundation for improved immunotherapy and prognosis and is beneficial to the individualized management of oral cancer patients.

References

Mao L, Wu X, Gong Z, Yu M, Huang Z . PDIA6 contributes to aerobic glycolysis and cancer progression in oral squamous cell carcinoma. World J Surg Oncol. 2021; 19(1):88. PMC: 7992853. DOI: 10.1186/s12957-021-02190-w. View

Eder T, Hess A, Konschak R, Stromberger C, Johrens K, Fleischer V . Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group. Eur J Cancer. 2019; 116:67-76. DOI: 10.1016/j.ejca.2019.04.015. View

Harrington K, Ferris R, Blumenschein Jr G, Colevas A, Fayette J, Licitra L . Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017; 18(8):1104-1115. PMC: 6461049. DOI: 10.1016/S1470-2045(17)30421-7. View

Donald C, Sun C, Lim S, Macoska J, Cohen C, Amin M . Cancer-specific loss of beta-defensin 1 in renal and prostatic carcinomas. Lab Invest. 2003; 83(4):501-5. DOI: 10.1097/01.lab.0000063929.61760.f6. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

Chi L, Hsiao Y, Chien K, Chen S, Chuang Y, Lin S . Assessment of candidate biomarkers in paired saliva and plasma samples from oral cancer patients by targeted mass spectrometry. J Proteomics. 2019; 211:103571. DOI: 10.1016/j.jprot.2019.103571. View

Batta N, Pandey M . Mutational spectrum of tobacco associated oral squamous carcinoma and its therapeutic significance. World J Surg Oncol. 2019; 17(1):198. PMC: 6882338. DOI: 10.1186/s12957-019-1741-2. View

Pandey M, Kannepali K, Dixit R, Kumar M . Effect of neoadjuvant chemotherapy and its correlation with HPV status, EGFR, Her-2-neu, and GADD45 expression in oral squamous cell carcinoma. World J Surg Oncol. 2018; 16(1):20. PMC: 5793383. DOI: 10.1186/s12957-018-1308-7. View

Burtness B, Harrington K, Greil R, Soulieres D, Tahara M, de Castro Jr G . Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10212):1915-1928. DOI: 10.1016/S0140-6736(19)32591-7. View

10.

Xin S, Fang W, Li J, Li D, Wang C, Huang Q . Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients. J Cancer Res Clin Oncol. 2021; 147(3):725-737. DOI: 10.1007/s00432-020-03476-4. View

11.

Lee D, Lee H, Kim J, Park I, Rho Y . Heavy alcohol drinking downregulates ALDH2 gene expression but heavy smoking up-regulates SOD2 gene expression in head and neck squamous cell carcinoma. World J Surg Oncol. 2017; 15(1):163. PMC: 6389042. DOI: 10.1186/s12957-017-1225-1. View

12.

Attaran N, Gu X, Coates P, Fahraeus R, Boldrup L, Wilms T . Downregulation of TAP1 in Tumor-Free Tongue Contralateral to Squamous Cell Carcinoma of the Oral Tongue, an Indicator of Better Survival. Int J Mol Sci. 2020; 21(17). PMC: 7503265. DOI: 10.3390/ijms21176220. View

13.

Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N . PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2012; 73(1):128-38. DOI: 10.1158/0008-5472.CAN-12-2606. View

14.

Lu S, Reh D, Li A, Woods J, Corless C, Kulesz-Martin M . Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res. 2004; 64(13):4405-10. DOI: 10.1158/0008-5472.CAN-04-1032. View

15.

Heikkinen I, Bello I, Wahab A, Hagstrom J, Haglund C, Coletta R . Assessment of Tumor-infiltrating Lymphocytes Predicts the Behavior of Early-stage Oral Tongue Cancer. Am J Surg Pathol. 2019; 43(10):1392-1396. DOI: 10.1097/PAS.0000000000001323. View

16.

Novy P, Quigley M, Huang X, Yang Y . CD4 T cells are required for CD8 T cell survival during both primary and memory recall responses. J Immunol. 2007; 179(12):8243-51. DOI: 10.4049/jimmunol.179.12.8243. View

17.

Luo J, Young C, Zhou H, Wang X . Mouse Models for Studying Oral Cancer: Impact in the Era of Cancer Immunotherapy. J Dent Res. 2018; 97(6):683-690. PMC: 6728551. DOI: 10.1177/0022034518767635. View

18.

Xu G, Wei J, Huangfu B, Gao J, Wang X, Xiao L . Animal model and bioinformatics analyses suggest the TIMP1/MMP9 axis as a potential biomarker in oral squamous cell carcinoma. Mol Carcinog. 2020; 59(11):1302-1316. DOI: 10.1002/mc.23258. View

19.

Cherdantseva T, Bobrov I, Avdalyan A, Klimachev V, Kazartsev A, Kryuchkova N . Mast Cells in Renal Cancer: Clinical Morphological Correlations and Prognosis. Bull Exp Biol Med. 2017; 163(6):801-804. DOI: 10.1007/s10517-017-3907-7. View

20.

Sun C, Arnold R, Fernandez-Golarz C, Parrish A, Almekinder T, He J . Human beta-defensin-1, a potential chromosome 8p tumor suppressor: control of transcription and induction of apoptosis in renal cell carcinoma. Cancer Res. 2006; 66(17):8542-9. DOI: 10.1158/0008-5472.CAN-06-0294. View